Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;8(1):39-45.
doi: 10.21037/tau.2019.01.15.

Prediction tools in non-muscle invasive bladder cancer

Stefania Zamboni  1   2 , Marco Moschini  1 , Claudio Simeone  2 , Alessandro Antonelli  2 , Agostino Mattei  1 , Philipp Baumeister  1 , Evanguelos Xylinas  3 , Oliver W Hakenberg  4 , Atiqullah Aziz  4
Affiliations
Review

Prediction tools in non-muscle invasive bladder cancer

Stefania Zamboni et al. Transl Androl Urol. 2019 Feb.

Abstract

Non-muscle invasive bladder cancer (BCa) is the second most common genitourinary malignancy, burdened by high rates of recurrence and progression. Urologist are encouraged to stratify patients on the bases of recurrence and progression risks in order to define the best therapeutic approach and follow-up scheme. For these reasons, the aim of the present non-systematic review was to assess the literature on prediction tools in non-muscle invasive BCa. Currently, the most widely used tools remain the European Organization for Research and Treatment of Cancer (EORTC) and the Club Urologico Espanol de Tratamiento Oncologico (CUETO) risk tables, which are based on clinicopathologic features. Recent external validations, therefore, reported their low accuracy, probably related to the lack of the role of re-transurethral resection (TURBT), early instillations, chemotherapy and complete BCG schedules in the studies included to asses these scores. More recently several immunological, biochemical and genetics biomarkers have been tested by themselves and in combination with clinicopathologic features, and many of them resulted related with risk of recurrence and progression. Future perspectives will presumably include the update of EORTC and CUETO scores with newest guidelines' recommendations and their integration with biomarkers.

Keywords: Bladder cancer (BCa); NMIBC; non-muscle invasive; progression; recurrence; tools.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
    1. Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61. 10.1016/j.eururo.2016.05.041 - DOI - PubMed
    1. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-5; discussion 475-7. - PubMed
    1. Mostofi FK, Sobin LH, Torloni H, et al. Histological Typing of Urinary Bladder Tumours. Geneva: World Health Organization, 1973.
    1. Xylinas E, Kent M, Kluth L, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carci-noma of the bladder. Br J Cancer 2013;109:1460-6. 10.1038/bjc.2013.372 - DOI - PMC - PubMed

LinkOut - more resources